Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. Issue 8 (3rd August 2021)

• Record Type: Journal Article
• Authors: Hossain, Md. Jamal; Rahman, S. M. Abdur
• Is Part Of: Expert review of anti-infective therapy. Volume 19:Issue 8(2021)
• Page Start: 1009
• Page End: 1027
• Publication Date: 2021-08-03
• Subjects: SARS-CoV-2 -- covid-19 pandemic -- public health crisis -- palliative care -- repurposing strategy -- clinical trials; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2021.1864327
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Introduction: The pathogenic and highly transmissible etiological agent, SARS-CoV-2, has caused a serious threat COVID-19 pandemic. WHO has declared the epidemic a public health emergency of international concern owing to its high contagiosity, mortality rate, and morbidity. Till now, there is no approved vaccine or drug to combat the COVID-19 and avert this global crisis. Areas covered: In this narrative review, we summarized the updated results (January to August 2020) of the most promising repurposing therapeutic candidates to treat the SARS-CoV-2 viral infection. The repurposed drugs classified under four headlines like antivirals, anti-parasitic, immune-modulating, and miscellaneous drugs were discussed with their in vitro efficacy to recent clinical advancements against COVID-19. Expert opinion: Currently, palliative care, ranging from outpatient management to intensive care, including oxygen administration, ventilator support, intravenous fluids therapy, with some repurposed drugs, are the primary weapons to fight against COVID-19. Until a safe and effective vaccine is developed, an evidence-based drug repurposing strategy might be the wisest option to save people from this catastrophe. Several existing drugs are now under clinical trials, and some of them are approved in different places of the world for emergency use or as adjuvant therapy in COVID-19 with standard of care.